On April 26, 2022 Argonaut Therapeutics, a leading developer of novel cancer agents, reported a company showcase presentation at the BioTrinity 2022 event, an international conference focused on bio-partnering and investment (Press release, Argonaut Therapeutics, APR 28, 2022, View Source [SID1234613196]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation to an audience of key industry investors and experts highlighted Argonaut Therapeutics vision to become a leading company in delivering innovative treatments to treat deadly cancers and provided an overview of the company’s proprietary assets and platforms, with an expanded focus on novel drug targets discovered in cancer relevant pathways.
About BioTrinity
BioTrinity is an established, must-attend London conference, that catalyses growth and supports in- person re-engagement across the life sciences industry. The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.
Professor Nick La Thangue, Founder and Chief Scientific Officer of Argonaut Therapeutics, and Professor of Cancer Biology in the Department of Oncology at Oxford University, commented:
"Arginine methylation is an extremely important process under aberrant control in many different cancers and drugs targeting arginine methylation will find clinical utility in diverse indications. We are delighted to have been invited to present in the oncology session at the BioTrinity 2022 event and share details on Argonaut’s novel and exciting asset pipeline".
Listen to Argonaut’s BioTrinity 2022 presentation here